|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
1 | AN ACT concerning State government.
| ||||||||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois,
| ||||||||||||||||||||||||
3 | represented in the General Assembly:
| ||||||||||||||||||||||||
4 | Section 5. The Newborn Metabolic Screening Act is amended | ||||||||||||||||||||||||
5 | by changing Section 2 as follows:
| ||||||||||||||||||||||||
6 | (410 ILCS 240/2) (from Ch. 111 1/2, par. 4904)
| ||||||||||||||||||||||||
7 | Sec. 2. The Department of Public Health shall administer | ||||||||||||||||||||||||
8 | the
provisions of this Act and shall:
| ||||||||||||||||||||||||
9 | (a) Institute and carry on an intensive educational program | ||||||||||||||||||||||||
10 | among
physicians, hospitals, public health nurses and the | ||||||||||||||||||||||||
11 | public concerning
the diseases phenylketonuria, | ||||||||||||||||||||||||
12 | hypothyroidism, galactosemia and other
metabolic diseases. | ||||||||||||||||||||||||
13 | This
educational program shall include information about the | ||||||||||||||||||||||||
14 | nature of the
diseases and examinations for the detection of | ||||||||||||||||||||||||
15 | the diseases in early
infancy in order that measures may be | ||||||||||||||||||||||||
16 | taken to prevent the mental
retardation resulting from the | ||||||||||||||||||||||||
17 | diseases.
| ||||||||||||||||||||||||
18 | (a-5) Beginning July 1, 2002, provide all newborns
with | ||||||||||||||||||||||||
19 | expanded screening tests for the presence of genetic, | ||||||||||||||||||||||||
20 | endocrine, or
other metabolic disorders, including | ||||||||||||||||||||||||
21 | phenylketonuria, galactosemia,
hypothyroidism, congenital | ||||||||||||||||||||||||
22 | adrenal hyperplasia, biotinidase deficiency,
and sickling | ||||||||||||||||||||||||
23 | disorders, as well as other amino acid disorders, organic
acid |
| |||||||
| |||||||
1 | disorders, fatty acid oxidation disorders, and other | ||||||
2 | abnormalities
detectable through the use of a tandem mass | ||||||
3 | spectrometer. If by July 1,
2002, the Department is unable to | ||||||
4 | provide expanded screening using the
State Laboratory, it shall | ||||||
5 | temporarily provide such screening
through an accredited | ||||||
6 | laboratory selected by the Department until the
Department has | ||||||
7 | the capacity to provide screening through the State
Laboratory. | ||||||
8 | If expanded screening is provided on a temporary basis
through | ||||||
9 | an accredited laboratory, the Department shall substitute the | ||||||
10 | fee
charged by the accredited laboratory, plus a 5% surcharge | ||||||
11 | for
documentation and handling, for the fee authorized in | ||||||
12 | subsection (e) of
this Section.
| ||||||
13 | (a-6) In accordance with the timetable specified in this | ||||||
14 | subsection, provide all newborns with expanded screening tests | ||||||
15 | for the presence of certain Lysosomal Storage Disorders known | ||||||
16 | as Krabbe, Pompe, Gaucher, Fabry, and Niemann-Pick. The testing | ||||||
17 | shall begin within 6 months following the occurrence of all of | ||||||
18 | the following: | ||||||
19 | (i) the registration with the federal Food and Drug | ||||||
20 | Administration of the necessary reagents; | ||||||
21 | (ii) the availability of the necessary reagents from | ||||||
22 | the Centers for Disease Control and Prevention; | ||||||
23 | (iii) the availability of quality assurance testing | ||||||
24 | methodology for these processes; and | ||||||
25 | (iv) the acquisition and installment by the Department | ||||||
26 | of the equipment necessary to implement the expanded |
| |||||||
| |||||||
1 | screening tests. | ||||||
2 | It is the goal of this amendatory Act of the 95th General | ||||||
3 | Assembly that the expanded screening for the specified | ||||||
4 | Lysosomal Storage Disorders begins within 3 years after the | ||||||
5 | effective date of this Act. The Department is authorized to | ||||||
6 | implement an additional fee for the screening prior to | ||||||
7 | beginning the testing in order to accumulate the resources for | ||||||
8 | start-up and other costs associated with implementation of the | ||||||
9 | screening and thereafter to support the costs associated with | ||||||
10 | screening and follow-up programs for the specified Lysosomal | ||||||
11 | Storage Disorders.
| ||||||
12 | (b) Maintain a registry of cases including information of | ||||||
13 | importance
for the purpose of follow-up services to prevent | ||||||
14 | mental retardation.
| ||||||
15 | (c) Supply the necessary metabolic treatment formulas
| ||||||
16 | where practicable for
diagnosed cases of amino acid metabolism | ||||||
17 | disorders, including phenylketonuria, organic acid disorders, | ||||||
18 | and fatty acid oxidation disorders for as long as medically | ||||||
19 | indicated, when the product is
not available through other | ||||||
20 | State agencies.
| ||||||
21 | (d) Arrange for or provide public health nursing, nutrition | ||||||
22 | and
social services and clinical consultation as indicated.
| ||||||
23 | (e) Require that all specimens collected pursuant to this | ||||||
24 | Act or the rules
and regulations promulgated hereunder be | ||||||
25 | submitted for testing to the nearest
Department of Public | ||||||
26 | Health laboratory designated to perform such tests.
The |
| |||||||
| |||||||
1 | Department may develop a reasonable fee structure and may levy | ||||||
2 | fees
according to such structure to cover the cost of providing | ||||||
3 | this testing
service. Fees collected from the provision of this | ||||||
4 | testing service shall
be placed in a special fund in the State | ||||||
5 | Treasury, hereafter known as the
Metabolic Screening and | ||||||
6 | Treatment Fund. Other State and federal funds for
expenses | ||||||
7 | related to metabolic screening, follow-up and treatment | ||||||
8 | programs
may also be placed in such Fund. Moneys shall be | ||||||
9 | appropriated from such
Fund to the Department of Public Health | ||||||
10 | solely for the purposes of providing
metabolic screening, | ||||||
11 | follow-up and treatment programs. The Metabolic Screening and | ||||||
12 | Treatment Fund is not subject to sweeps, administrative | ||||||
13 | charges, or charge-backs, including but not limited to those | ||||||
14 | authorized under Section 8h of the State Finance Act, or any | ||||||
15 | other fiscal or budgetary maneuver that would in any way | ||||||
16 | transfer any funds from the Metabolic Screening and Treatment | ||||||
17 | Fund into any other fund of the State. Nothing in this
Act | ||||||
18 | shall be construed to prohibit any licensed medical facility | ||||||
19 | from
collecting
additional specimens for testing for metabolic | ||||||
20 | or neonatal diseases or any
other diseases or conditions, as it | ||||||
21 | deems fit. Any person
violating the provisions of this | ||||||
22 | subsection (e) is guilty of a petty offense.
| ||||||
23 | (Source: P.A. 95-695, eff. 11-5-07.)
| ||||||
24 | Section 99. Effective date. This Act takes effect upon | ||||||
25 | becoming law.
|